Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Cadrenal Therapeutics Receives FDA Orphan Drug Designation For Tecarfarin For Prevention Of Thromboembolism And Thrombosis In Patients With LVADs, RVADs, Biventricular Assist Devices, And Total Artificial Hearts

Author: Benzinga Newsdesk | April 09, 2024 09:05am

FDA designation provides potentially seven years of market exclusivity after approval and expanded partnering opportunities for tecarfarin

Posted In: CVKD